AMN Healthcare (AMN) PT Lowered to $22 at Citizens

Citizens analyst Constantine Davides lowered the price target on AMN Healthcare (NYSE: AMN) to $22.00 (from $24.00) while maintaining a Market Outperform rating.

The analyst commented, "We have updated our 2026 and 2027 AMN Healthcare (AMN, MO, $22 PT) EBITDA estimates to reflect a more tempered margin build than our prior model while maintaining our revenue forecasts. We lower our 12-month price target by $2 to $22, which is derived by applying an 8x multiple against our revised 2026 EBITDA estimate of $182M (roughly 1% above our estimate of revised consensus). AMN recently traded at 7.9x our NTM EBITDA estimate, at the low end of a more normalized (pre-COVID) range of ~7.5x-11.5x."

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform